Cargando…

Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials

Combination antiretroviral therapy (cART) has transformed HIV from a deadly to a chronic disease, but HIV patients are still burdened with excess morbidity and mortality, long-term toxicities from cART, stigmatization, and insufficient access to cART worldwide. Thus, a cure for HIV would have enormo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rasmussen, Thomas A., Tolstrup, Martin, Winckelmann, Anni, Østergaard, Lars, Søgaard, Ole S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903897/ https://www.ncbi.nlm.nih.gov/pubmed/23563519 http://dx.doi.org/10.4161/hv.23202

Ejemplares similares

Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients
por: Winckelmann, Anni A., et al.
Publicado: (2013)

Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals
por: Winckelmann, Anni, et al.
Publicado: (2018)

Broad activation of latent HIV-1 in vivo
por: Barton, Kirston, et al.
Publicado: (2016)

Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations
por: Winckelmann, Anni, et al.
Publicado: (2017)

Immune checkpoints and the HIV-1 reservoir: proceed with caution
por: Olesen, Rikke, et al.
Publicado: (2016)

Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues
por: Denton, Paul W., et al.
Publicado: (2019)

Comparison of HDAC inhibitors in clinical development: Effect on HIV production in latently infected cells and T-cell activation
por: Rasmussen, Thomas Aagaard, et al.
Publicado: (2013)

A5 Peripheral blood cells contribute to HIV-1 viremia induced by romidepsin
por: Winckelmann, A., et al.
Publicado: (2017)

Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs
por: Sadowski, Ivan, et al.
Publicado: (2019)

Implications of HIV-1 Nef for “Shock and Kill” Strategies to Eliminate Latent Viral Reservoirs
por: Kuang, Xiaomei T., et al.
Publicado: (2018)

DC-based immunotherapy as strategy to purge the HIV reservoir?
por: Søgaard, Ole S.
Publicado: (2019)

Activation of Latent Human Immunodeficiency Virus by the Histone Deacetylase Inhibitor Panobinostat: A Pilot Study to Assess Effects on the Central Nervous System
por: Rasmussen, Thomas A., et al.
Publicado: (2015)

Efforts to eliminate the latent reservoir in resting CD4+ T cells: strategies for curing HIV-1 infection
por: Ho, Ya-Chi, et al.
Publicado: (2015)

Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1
por: Sanz, Marta, et al.
Publicado: (2023)

Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1
por: Sanz, Marta, et al.
Publicado: (2023)

The reservoir of latent HIV
por: Chen, Jing, et al.
Publicado: (2022)

TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults
por: Offersen, Rasmus, et al.
Publicado: (2012)

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation
por: Gunst, Jesper D, et al.
Publicado: (2019)

Block and Lock HIV Cure Strategies to Control the Latent Reservoir
por: Ahlenstiel, Chantelle L., et al.
Publicado: (2020)

The latent HIV reservoir: current advances in genetic sequencing approaches
por: Moar, Preeti, et al.
Publicado: (2023)

Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs
por: Brockman, Mark A., et al.
Publicado: (2015)

Regulatory B Cells Inhibit Cytotoxic T Lymphocyte (CTL) Activity and Elimination of Infected CD4 T Cells after In Vitro Reactivation of HIV Latent Reservoirs
por: Siewe, Basile, et al.
Publicado: (2014)

Strategies for enhancing CAR T cell expansion and persistence in HIV infection
por: Rothemejer, Frederik Holm, et al.
Publicado: (2023)

Insights into the HIV-1 Latent Reservoir and Strategies to Cure HIV-1 Infection
por: Bai, Ruojing, et al.
Publicado: (2022)

The Impact of B-Cell Perturbations on Pneumococcal Conjugate Vaccine Response in HIV-Infected Adults
por: Johannesson, Thomas G., et al.
Publicado: (2012)

Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection
por: Zurek Munk-Madsen, Maria, et al.
Publicado: (2017)

Heterogeneity of HIV-1 latent reservoirs
por: Zhao, Jia-Cong, et al.
Publicado: (2020)

Brain HIV-1 latently-infected reservoirs targeted by the suicide gene strategy
por: Saeb, Sepideh, et al.
Publicado: (2021)

The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies
por: Martinsen, Janne Tegder, et al.
Publicado: (2020)

HCMV Antivirals and Strategies to Target the Latent Reservoir
por: Perera, Marianne R., et al.
Publicado: (2021)

Measuring replication competent HIV-1: advances and challenges in defining the latent reservoir
por: Wang, Zheng, et al.
Publicado: (2018)

HIV-1 latent reservoir: size matters
por: Hodel, Flavia, et al.
Publicado: (2016)

Endotoxemia Is Associated with Altered Innate and Adaptive Immune Responses in Untreated HIV-1 Infected Individuals
por: Bukh, Anne Roslev, et al.
Publicado: (2011)

Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research
por: Denton, Paul W., et al.
Publicado: (2016)

HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
por: Pinkevych, Mykola, et al.
Publicado: (2015)

Targeting the latent reservoir to achieve functional HIV cure
por: Cary, Daniele C., et al.
Publicado: (2016)

Establishment and stability of the latent HIV-1 DNA reservoir
por: Brodin, Johanna, et al.
Publicado: (2016)

Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days—Implications for HIV Remission
por: Pinkevych, Mykola, et al.
Publicado: (2016)

Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients
por: Bjerg Christensen, Ane, et al.
Publicado: (2015)

Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5–8 Days
por: Pinkevych, Mykola, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_er6pbc9bj5f1u6s2jl8c3okrg8